Mammalian topoisomerase II inhibitory activity of 1-cyclopropyl-6,8- difluoro-1,4-dihydro-7-(2,6-dimethyl-4-pyridinyl)-4-oxo-3-quinolinecarb oxylic acid and related derivatives. 1993

M P Wentland, and G Y Lesher, and M Reuman, and M D Gruett, and B Singh, and S C Aldous, and P H Dorff, and J B Rake, and S A Coughlin
Department of Medicinal Chemistry, Sterling Winthrop Pharmaceuticals Research Division, Sterling Winthrop Inc., Collegeville, Pennsylvania 19426-0900.

1-Cyclopropyl-6,8-difluoro-1,4-dihydro-7-(2,6-dimethyl-4-pyridinyl)-4-ox o-3-quinolinecarboxylic acid (1), a previously reported potent inhibitor of bacterial DNA gyrase, was found to be interactive with mammalian topoisomerase II (topo II). In a DNA-cleavage assay using topo II isolated from HeLa cells, 1 exhibited an EC50 value of 7.6 microM (VP-16; EC50 = 0.81 microM). A series of analogues modified at the 1-, 2-, 3-, 5-, and 7-positions of 1 were subsequently made and assessed for topo II inhibition. Compound 1 was considerably more potent than derivatives where the 1-substituent was alkyl, aryl, or H, or when N-c-C3H5 was replaced with S. The descarboxyl (i.e., 3-H) analogue had potency comparable to that of 1; when both these compounds were substituted at the 2-position with methyl or phenyl, an interesting relationship between activity and the conformation of the carboxyl group emerged. Upon replacement of the 5-H of 1 with NH2 or F, sustained potency was seen. No enhancement of activity was evident upon replacing the 7-substituent of 1 with other pyridinyl groups, 4-methyl-1-piperazinyl, or pyrrolidinyl groups; however, the 7-(4-hydroxyphenyl) analogue (CP-115,953) was 6-fold more potent than 1. The topo II inhibitory properties of 1 translated to modest in vitro cytotoxicity and in vivo activity versus P388.

UI MeSH Term Description Entries
D007941 Leukemia P388 An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene. P388D(1) Leukemia,P388, Leukemia
D006367 HeLa Cells The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for, among other things, VIRUS CULTIVATION and PRECLINICAL DRUG EVALUATION assays. Cell, HeLa,Cells, HeLa,HeLa Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000890 Anti-Infective Agents Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. Anti-Infective Agent,Anti-Microbial Agent,Antimicrobial Agent,Microbicide,Microbicides,Anti-Microbial Agents,Antiinfective Agents,Antimicrobial Agents,Agent, Anti-Infective,Agent, Anti-Microbial,Agent, Antimicrobial,Agents, Anti-Infective,Agents, Anti-Microbial,Agents, Antiinfective,Agents, Antimicrobial,Anti Infective Agent,Anti Infective Agents,Anti Microbial Agent,Anti Microbial Agents
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015363 Quinolones A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID. Ketoquinoline,Ketoquinolines,Oxoquinoline,Oxoquinolines,Quinolinone,Quinolinones,Quinolone
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D059005 Topoisomerase II Inhibitors Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. DNA Gyrase Inhibitor,DNA Topoisomerase II Inhibitor,Topoisomerase 2 Inhibitors,Topoisomerase II Inhibitor,DNA Gyrase Inhibitors,DNA Topoisomerase II Inhibitors,DNA Type 2 Topoisomerase Inhibitors,Gyrase Inhibitor, DNA,Gyrase Inhibitors, DNA,II Inhibitor, Topoisomerase,Inhibitor, DNA Gyrase,Inhibitor, Topoisomerase II,Inhibitors, DNA Gyrase,Inhibitors, Topoisomerase 2,Inhibitors, Topoisomerase II
D024841 Fluoroquinolones A group of QUINOLONES with at least one fluorine atom and a piperazinyl group. Fluoroquinolone

Related Publications

M P Wentland, and G Y Lesher, and M Reuman, and M D Gruett, and B Singh, and S C Aldous, and P H Dorff, and J B Rake, and S A Coughlin
October 1992, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan,
M P Wentland, and G Y Lesher, and M Reuman, and M D Gruett, and B Singh, and S C Aldous, and P H Dorff, and J B Rake, and S A Coughlin
January 1993, Chemical & pharmaceutical bulletin,
M P Wentland, and G Y Lesher, and M Reuman, and M D Gruett, and B Singh, and S C Aldous, and P H Dorff, and J B Rake, and S A Coughlin
October 1987, Journal of medicinal chemistry,
M P Wentland, and G Y Lesher, and M Reuman, and M D Gruett, and B Singh, and S C Aldous, and P H Dorff, and J B Rake, and S A Coughlin
March 1988, Journal of medicinal chemistry,
M P Wentland, and G Y Lesher, and M Reuman, and M D Gruett, and B Singh, and S C Aldous, and P H Dorff, and J B Rake, and S A Coughlin
December 2011, Acta crystallographica. Section E, Structure reports online,
M P Wentland, and G Y Lesher, and M Reuman, and M D Gruett, and B Singh, and S C Aldous, and P H Dorff, and J B Rake, and S A Coughlin
April 1986, Journal of medicinal chemistry,
M P Wentland, and G Y Lesher, and M Reuman, and M D Gruett, and B Singh, and S C Aldous, and P H Dorff, and J B Rake, and S A Coughlin
January 1988, Drugs under experimental and clinical research,
M P Wentland, and G Y Lesher, and M Reuman, and M D Gruett, and B Singh, and S C Aldous, and P H Dorff, and J B Rake, and S A Coughlin
May 1998, Yao xue xue bao = Acta pharmaceutica Sinica,
M P Wentland, and G Y Lesher, and M Reuman, and M D Gruett, and B Singh, and S C Aldous, and P H Dorff, and J B Rake, and S A Coughlin
October 2010, Acta crystallographica. Section E, Structure reports online,
M P Wentland, and G Y Lesher, and M Reuman, and M D Gruett, and B Singh, and S C Aldous, and P H Dorff, and J B Rake, and S A Coughlin
August 1986, Journal of chromatography,
Copied contents to your clipboard!